FEMASYS INC (FEMY) Latest Company News

Nov 2, 2026, 21:17 UTC
Femasys said Kenneth D. Eichenbaum resigned as a director and John Moorhead was appointed as a director, effective October 30, 2026.
Oct 20, 2026, 13:00 UTC
FEMASYS INC partnered with SandsRx Pharmacy to support the launch of its FemaSeed fertility portfolio to OB/GYNs, providing medication coordination and preferred pricing for physicians and patients.
Source:
- globenewswire.com
Oct 14, 2026, 13:00 UTC
FEMASYS INC doubled the number of enrolling sites in its FemBloc FINALE pivotal trial to 12 academic and private clinical sites across the United States.
Source:
- globenewswire.com
Sep 15, 2026, 13:00 UTC
Femasys Inc. announced that Minnesota Women's Care will implement FemVue for fertility diagnostic evaluation and FemaSeed Complete for in-office first-line fertility treatment across its four OB/GYN practice locations.
Source:
- globenewswire.com
Sep 9, 2026, 13:00 UTC
Femasys Inc. announced a partnership with CapexMD to expand patient access to its FemaSeed fertility portfolio through dedicated financing solutions.
Source:
- globenewswire.com
Aug 26, 2026, 13:00 UTC
Femasys Inc. announced a partnership with UNC Health to introduce its fertility products FemVue, SpermVue, and FemaSeed Complete across UNC Health OB/GYN practice locations.
Source:
- globenewswire.com
Aug 19, 2026, 17:36 UTC
The U.S. Food and Drug Administration (FDA) authorized the modular premarket approval application pathway for Femasys's FemBloc non-surgical permanent birth control technology on Wednesday.
Source:
- benzinga.com
Aug 14, 2026, 20:05 UTC
Femasys Inc. announced its financial results for the quarter ended June 30, 2026.
Source:
- globenewswire.com
Aug 7, 2026, 13:25 UTC
Femasys Inc. announced a $30 million private placement of securities with accredited investors, led by Nantahala Capital, with potential additional proceeds of up to $90 million from warrant exercises, expected to close around August 10, 2026.
Source:
Jun 24, 2026, 13:00 UTC
Femasys Inc. received formal notice from Nasdaq confirming it has regained compliance with the minimum bid price listing requirement.
Source:
- globenewswire.com

FEMY

Femasys said Kenneth D. Eichenbaum resigned as a director and John Moorhead was appointed as a director, effective October 30, 2026.

FEMASYS INC partnered with SandsRx Pharmacy to support the launch of its FemaSeed fertility portfolio to OB/GYNs, providing medication coordination and preferred pricing for physicians and patients.

FEMASYS INC doubled the number of enrolling sites in its FemBloc FINALE pivotal trial to 12 academic and private clinical sites across the United States.

Femasys Inc. announced that Minnesota Women's Care will implement FemVue for fertility diagnostic evaluation and FemaSeed Complete for in-office first-line fertility treatment across its four OB/GYN practice locations.

Femasys Inc. announced a partnership with CapexMD to expand patient access to its FemaSeed fertility portfolio through dedicated financing solutions.

Femasys Inc. announced a partnership with UNC Health to introduce its fertility products FemVue, SpermVue, and FemaSeed Complete across UNC Health OB/GYN practice locations.

The U.S. Food and Drug Administration (FDA) authorized the modular premarket approval application pathway for Femasys's FemBloc non-surgical permanent birth control technology on Wednesday.

Femasys Inc. announced its financial results for the quarter ended June 30, 2026.

Femasys Inc. announced a $30 million private placement of securities with accredited investors, led by Nantahala Capital, with potential additional proceeds of up to $90 million from warrant exercises, expected to close around August 10, 2026.

Femasys Inc. received formal notice from Nasdaq confirming it has regained compliance with the minimum bid price listing requirement.